Many observers believe that pharmaceutical firms prefer to invest in drugs to treat diseases rather than vaccines. This column presents an economic rationale for why such a pattern may emerge for diseases like HIV/AIDS. The population risk of such diseases resembles a Zipf distribution, which makes the shape of the demand curve for a drug more conducive to revenue extraction than for a vaccine. Based on revenue calibrations using US data on HIV risk, the revenue from a drug is about four times greater.
Michael Kremer, Christopher Snyder, Natalia Drozdoff, 29 January 2016
Most Read
-
Danielsson
-
Funke, Schularick, Trebesch
-
Diao, Ellis, McMillan, Rodrik
-
Behrens, Kichko, Thisse
-
Goodhart, Masciandaro, Ugolini
-
Eichengreen, O'Rourke
-
Burgess, Sievertsen
-
Mitze, Kosfeld, Rode, Wälde
-
Heldring, Robinson
-
Eichengreen
Blogs&Reviews
-
Bouwens
-
Gaspar, Larraín Bascuñán
-
Evenett
-
Arezki, Rota-Graziosi
-
Gual
Vox eBooks
Don't Miss
Arezki, Djankov, Panizza
Bartsch, Bénassy-Quéré, Corsetti, Debrun
Scheuer
Events
-
4 - 4 March 2021 / Zoom webinar / World Trade Organization
-
10 - 10 March 2021 / Online /
-
11 - 11 March 2021 / Online /
-
12 - 12 March 2021 / Online /
-
15 March - 31 May 2021 / Online /
CEPR Policy Research
-
Gobillon, Solignac
-
Giglio, Maggiori, Stroebel, Weber
-
Summers, Fatás
-
Favero, Galasso
-
Butt, Churm, McMahon, Morotz, Schanz
-
Eichengreen, Avgouleas, Poiares Maduro, Panizza, Portes, Weder di Mauro, Wyplosz, Zettelmeyer
-
Baldwin, Beck, Bénassy-Quéré, Blanchard, Corsetti, De Grauwe, den Haan, Giavazzi, Gros, Kalemli-Ozcan, Micossi, Papaioannou, Pesenti, Pissarides , Tabellini, Weder di Mauro
-
Baldwin, Nakatomi
-
Thimann
-
Goodhart, Perotti